Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Oscier

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Haematologica|August 18, 2012
CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genesDavid Gonzalez, Monica Else, Dorte Wren, et al.
British Journal of Haematology|June 14, 2016
Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalitiesIan Tracy, William Tapper, Anton Parker, et al.
British Journal of Haematology|February 6, 2016
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identityZadie Davis, Francesco Forconi, Anton Parker, et al.
Hemasphere|April 8, 2022
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and RecommendationsPanagiotis Baliakas, Blanca Espinet, Clemens Mellink, et al.
Experimental Cell Research|July 14, 2009
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1Mikael Lerner, Masako Harada, Jakob Lovén, et al.
Blood|March 1, 2003
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal diseaseJenny Orchard, Richard Garand, Zadie Davis, et al.
Leukemia & Lymphoma|January 7, 2016
Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survivalGuy Pratt, Peter Thomas, Nicola Marden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trialDavid Gonzalez, Pilar Martinez, Rachel Wade, et al.
Electrophoresis|June 2, 2005
Capillary electrophoresis-laser induced fluorescence analysis of endogenous damage in mitochondrial and genomic DNAMichaela Wirtz, Claus A Schumann, Marc Schellenträger, et al.
Genes, Chromosomes & Cancer|January 22, 2008
The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1Claire Hidalgo-Curtis, Andrew Chase, Milton Drachenberg, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Haematologica|August 18, 2012
CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genesDavid Gonzalez, Monica Else, Dorte Wren, et al.
British Journal of Haematology|June 14, 2016
Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalitiesIan Tracy, William Tapper, Anton Parker, et al.
British Journal of Haematology|February 6, 2016
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identityZadie Davis, Francesco Forconi, Anton Parker, et al.
Hemasphere|April 8, 2022
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and RecommendationsPanagiotis Baliakas, Blanca Espinet, Clemens Mellink, et al.
Experimental Cell Research|July 14, 2009
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1Mikael Lerner, Masako Harada, Jakob Lovén, et al.
Blood|March 1, 2003
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal diseaseJenny Orchard, Richard Garand, Zadie Davis, et al.
Leukemia & Lymphoma|January 7, 2016
Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survivalGuy Pratt, Peter Thomas, Nicola Marden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trialDavid Gonzalez, Pilar Martinez, Rachel Wade, et al.
Electrophoresis|June 2, 2005
Capillary electrophoresis-laser induced fluorescence analysis of endogenous damage in mitochondrial and genomic DNAMichaela Wirtz, Claus A Schumann, Marc Schellenträger, et al.
Genes, Chromosomes & Cancer|January 22, 2008
The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1Claire Hidalgo-Curtis, Andrew Chase, Milton Drachenberg, et al.
Pageof 10